Current Report Filing (8-k)
17 Marzo 2023 - 9:06PM
Edgar (US Regulatory)
0001006028
false
0001006028
2023-03-17
2023-03-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 17, 2023
PURE
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-14468 |
|
33-0530289 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
9669
Hermosa Avenue
Rancho
Cucamonga, California |
|
91730 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (619) 596-8600
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
March 17, 2023, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal
quarter ended January 31, 2023 and related information. A copy of the press release is attached as Exhibit 99.1.
The
information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated
by reference into any registration statement or other document filed with the Securities and Exchange Commission.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
| * |
Exhibit
99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration
statement or other document filed with the Securities and Exchange Commission. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
PURE
BIOSCIENCE, INC. |
| |
|
|
| Dated:
March 17, 2023 |
By:
|
/s/
Robert F. Bartlett |
| |
|
Robert
F. Bartlett |
| |
|
Chief
Executive Officer |
EXHIBIT
INDEX
Grafico Azioni PURE Bioscience (PK) (USOTC:PURE)
Storico
Da Mar 2025 a Mar 2025
Grafico Azioni PURE Bioscience (PK) (USOTC:PURE)
Storico
Da Mar 2024 a Mar 2025
Notizie in Tempo Reale relative a PURE Bioscience Inc (PK) (OTCMarkets): 0 articoli recenti
Più Pure Bioscience, Inc. Articoli Notizie
